Lindt Says U.S. Weight-Loss Drug Users are Eating More Chocolate

Chocolate sales are rising faster among US users of GLP-1 weight-loss drugs than among the broader population, Swiss chocolatier Lindt & Spruengli said, citing new consumer data that challenges predictions that the drugs would dampen demand for sweets, Reuters reported.

Lindt said US sales of premium chocolate among GLP-1 users increased by nearly 17% in 2025, compared with 6.5% growth among non-users. (Photo: Lindt Facebook) 

The company said an internal study based on February data from market researcher Circana found that 15% of US households use GLP-1 drugs, accounting for 17.5% of chocolate sales.

GLP-1 medications include weight-loss drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro.

Consumers cutting back on high-calorie foods such as pasta, pizza and potato chips are still seeking small indulgences, Lindt CEO Adalbert Lechner said during a news conference.

“They are upgrading to premium products. Less is more—small rewards with a moment of bliss rather than mindless munching,” Lechner said.

Lindt said US sales of premium chocolate among GLP-1 users increased by nearly 17% in 2025, compared with 6.5% growth among non-users.

Some analysts had predicted that GLP-1 drugs would hurt confectionery demand in the coming years. Analysts at Berenberg had expected the drugs to reduce Lindt’s sales volumes by about 0.9 percentage point by 2027.